tDCS Associated With Peripheral Electrical Stimulation for Pain Control in Individuals With Sickle Cell Disease
Unknown statusPhase 2NCT02813629
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
So far, no study investigated the safety and efficacy analgesic of transcranial direct current stimulation (tDCS) associated to peripheral electrical stimulation (PES) in individuals with SCD who suffer from chronic pain. Several studies have reported a decrease in O²Hb concentration in the regions below the electrodes and in other cortical areas during anodic or cathodic tDCS, which implies a risk factor for vasoocclusive events in individuals with SDC due to polymerization of hemoglobin when exposed to these low O²Hb concentrations. For this reasion, the aim main of this study is to assess the effect of a single session of transcranial direct current stimulation (tDCS) associated to peripheral electrical stimulation (PES) on safety and efficacy analgesic in individuals with sickle cell disease (SCD). Others aims sencondaries are evaluate the effect of a single session of transcranial direct current stimulation (tDCS) associated to peripheral electrical stimulation (PES) on biomarkers neurophysiological and inflammatory.
Study details
- Official title
- Transcranial Direct Current Stimulation Associated With Peripheral Electrical Stimulation for Pain Control in Individuals With Sickle Cell Disease
- Conditions
- Anemia, Sickle Cell
- Chronic Pain
- Interventions
- Device: tDCS plus PES
- Sponsor
- Faculdade Adventista da Bahia
- Collaborators
- Federal University of Bahia
- Start date
- 2016-03
- Primary completion
- 2022-12
- Sex
- All
- Age range
- from 18 Years to 50 Years
- Healthy volunteers
- true
- Results posted
- No results posted in this snapshot
- Countries
- Brazil
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Being diagnosed with sickle cell disease hemoglobin electrophoresis. * Be aged 18 years old to 50 years old. * Having signed the consent form and clarified. * Having chronic pain with at least 3 months duration. * Being diagnosed with femoral head osteonecrosis * Have more than one type of chronic pain. Exclusion Criteria: * Have cochlear implants, pacemakers or metallic implant in the skull / brain; * Have metallic implant application site of peripheral stimulation; * History of head trauma; * Pregnancy; * seizures or epilepsy History; * Being in drug use that modify neuronal activation threshold (eg antidepressants and anticonvulsants); * Having diagnosis of fibromyalgia, or any impairment to be confused with the symptoms of SCD; * Have pain confirmed neuropathic type.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT02813629